Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Investigational New Drugs
|
October 16, 2009
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining
Rafal Wierzbicki, Derek J Jonker, Malcolm J Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2010
Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs
Scott R Berry, Chaim M Bell, Peter A Ubel, et al.
JCO Global Oncology
|
June 17, 2021
Tracking the Workforce 2020-2030: Making the Case for a Cancer Workforce Registry
Archita Srivastava, Matthew Jalink, Fabio Ynoe de Moraes, et al.
Oncology Nursing Forum
|
July 7, 2015
A Qualitative Study Exploring the Perceptions of Sedentary Behavior in Prostate Cancer Survivors Receiving Androgen-Deprivation Therapy
Linda Trinh, Kelly P Arbour-Nicitopoulos, Catherine M Sabiston, et al.
The International Journal of Behavioral Nutrition and Physical Activity
|
December 6, 2018
Correction to: RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy
Linda Trinh, Kelly P Arbour-Nicitopoulos, Catherine M Sabiston, et al.
Journal of Oncology Practice
|
May 5, 2016
Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer
Maria Carmen Riesco-Martínez, Scott R Berry, Yoo-Joung Ko, et al.
The International Journal of Behavioral Nutrition and Physical Activity
|
June 9, 2018
RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy
Linda Trinh, Kelly P Arbour-Nicitopoulos, Catherine M Sabiston, et al.
Health Affairs (Project Hope)
|
April 12, 2012
In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival
Peter A Ubel, Scott R Berry, Eric Nadler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2011
American society of clinical oncology statement: toward individualized care for patients with advanced cancer
Jeffrey M Peppercorn, Thomas J Smith, Paul R Helft, et al.
The New England Journal of Medicine
|
November 16, 2007
Cetuximab for the treatment of colorectal cancer
Derek J Jonker, Chris J O'Callaghan, Christos S Karapetis, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Investigational New Drugs
|
October 16, 2009
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining
Rafal Wierzbicki, Derek J Jonker, Malcolm J Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2010
Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs
Scott R Berry, Chaim M Bell, Peter A Ubel, et al.
JCO Global Oncology
|
June 17, 2021
Tracking the Workforce 2020-2030: Making the Case for a Cancer Workforce Registry
Archita Srivastava, Matthew Jalink, Fabio Ynoe de Moraes, et al.
Oncology Nursing Forum
|
July 7, 2015
A Qualitative Study Exploring the Perceptions of Sedentary Behavior in Prostate Cancer Survivors Receiving Androgen-Deprivation Therapy
Linda Trinh, Kelly P Arbour-Nicitopoulos, Catherine M Sabiston, et al.
The International Journal of Behavioral Nutrition and Physical Activity
|
December 6, 2018
Correction to: RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy
Linda Trinh, Kelly P Arbour-Nicitopoulos, Catherine M Sabiston, et al.
Journal of Oncology Practice
|
May 5, 2016
Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer
Maria Carmen Riesco-Martínez, Scott R Berry, Yoo-Joung Ko, et al.
The International Journal of Behavioral Nutrition and Physical Activity
|
June 9, 2018
RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy
Linda Trinh, Kelly P Arbour-Nicitopoulos, Catherine M Sabiston, et al.
Health Affairs (Project Hope)
|
April 12, 2012
In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival
Peter A Ubel, Scott R Berry, Eric Nadler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2011
American society of clinical oncology statement: toward individualized care for patients with advanced cancer
Jeffrey M Peppercorn, Thomas J Smith, Paul R Helft, et al.
The New England Journal of Medicine
|
November 16, 2007
Cetuximab for the treatment of colorectal cancer
Derek J Jonker, Chris J O'Callaghan, Christos S Karapetis, et al.
Page
of 3